期刊名称：NEUROCHEMISTRY INTERNATIONAL
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Neurochemistry International is devoted to the rapid publication of outstanding original articles and timely reviews in neurochemistry. Manuscripts on a broad range of topics will be considered, including molecular and cellular neurochemistry, neuropharmacology and genetic aspects of CNS function, neuroimmunology, metabolism as well as the neurochemistry of neurological and psychiatric disorders of the CNS.
Audience
Neurochemists and all those with an interest in the nervous system.
Abstracting / Indexing
- BIOSIS
- Chemical Abstracts
- Current Contents/ISI/BIOMED Database
- Current Contents/Life Sciences
- Current Contents/SciSearch Database
- Current Contents/Science Citatation Index
- EMBASE
|
- Elsevier BIOBASE
- Index Medicus
- Medline
- PASCAL/CNRS
- Psychology Abstracts
- Research Alert
|
Instructions to Authors
I. General
Neurochemistry International is devoted to the rapid publication of outstanding original articles and timely reviews in neurochemistry. Manuscripts on a broad range of topics will be considered, including molecular and cellular neurochemistry, neuropharmacology and genetic aspects of CNS function, neuroimmunology, metabolism as well as the neurochemistry of neurological and psychiatric disorders of the CNS.
1. Types of communication
(a) Papers reporting original research are considered for publication provided that they describe significant, new and carefully confirmed findings and that adequate experimental details are given. All papers must be prepared according to the instructions given in Section III.
(b) Rapid Communications are those reporting original research and which are considered of such importance that publication is necessary within the shortest possible time. These papers should be between 1000 and 4000 words in length, and will be published within 10 weeks of acceptance. When submitting a manuscript for publication as a rapid communication, authors should include a brief statement justifying the reason for its inclusion in the rapid publication section of the journal.
(c) Reviews on a specific topic of neurochemistry written at the invitation of the Editors-in-Chief or submitted directly by any author will be considered. These need not only be exhaustive reviews, but can also be shorter articles intended either to draw attention to developments in a specific field for workers in other scientific disciplines, or to bring together observations over a wide area which seem to point in a new direction, to give the author's personal views on a controversial topic, or to direct soundly based criticism at some widely held dogma or widely used technique in neuroscience. Authors should always endeavour to make their reviews understandable to neuroscientists of other disciplines.
2. Submission.
All manuscripts should initially be submitted to one of the Editors-in-Chief, i.e. either to Sylvester Vizi or to Roger Butterworth.
3. Refereeing. Every manuscript received by the Editors-in-Chief will be refereed by at least two specialists (who may or may not be members of the Editorial Advisory Board). The final decision on the acceptance of a manuscript will lie with the Editors-in-Chief and/or the Associate Editors, who will act on the advice of the referees.
4. Submission of manuscripts to Neurochemistry International will be held to imply that they represent original research not previously published (except in the form of an abstract or preliminary report) and that they are not being considered for publication elsewhere in similar form, in any language, without the consent of the publishers.
5. Authors are encouraged to submit a computer disk (5.25" or 3.5" HD/DD disk) containing the final version of the papers along with the final manuscript to the office of the appropriate Editor-in-Chief. Please observe the following criteria:
(a) Send only hard copy (i.e. no disk) when first submitting your paper.
(b) When your paper has been refereed, revised if necessary and accepted, send a disk containing the final version with the final hard copy. Make sure that the disk and the hard copy match exactly.
(c) Specify what software was used, including which release, e.g. WordPerfect 5.1.
(d) Specify what computer was used (either IBM-compatible PC or Apple Macintosh).
(e) Include the text file and separate table and illustration files, if available.
(f) The file should follow the general instructions on style/arrangement and, in particular, the reference style of this journal as given in the Instructions to Authors.
(g) The file should be one and a half or double spaced and should use the wrap-around end of line feature, i.e. no returns at the end of each line. All textual elements should begin flush left; no paragraph indents. Place two returns after every element such as title, headings, paragraphs, figure and table call-outs.
(h) Keep a back-up disk for reference and safety.
6. Reprints of each paper can be obtained at reasonable costs by ordering on the reprint order form supplied with the proofs. There will be no page charges and 25 reprints will be provided free of charge.
7. Proofs Proofs will be sent to the author (first-named author if no corresponding author is identified on multi-authored papers) by PDF wherever possible and should be returned within 48 hours of receipt, preferably by e-mail. Corrections should be restricted to typesetting errors; any other amendments made may be charged to the author. Any queries should be answered in full. Elsevier will do everything possible to get your article corrected and published as quickly and accurately as possible, Therefore, it is important that all of your corrections are returned to us in one all-inclusive e-mail or fax. Subsequent additional corrections will not be possible, so please ensure that your first communication is complete. Should you choose to mail your corrections, please return them to: Log-in Department, Elsevier, Stover Court, Bampfylde Street, Exeter, Devon, EX1 2AH, UK.
II. Experimental Procedures
All experiments on human subjects should be conducted in accordance with the Declaration of Helsinki. Manuscripts must be accompanied by a statement that all procedures were carried out with the adequate understanding and written consent of the subjects.
All animal experiments should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, the European Communities Council Directive of 24 November 1986 (86/609/EEC) or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 80-23, revised 1978).
Manuscripts should be accompanied by a statement that all efforts were made to minimize animal suffering, to reduce the number of animals used, and to utilize alternatives to in vivo techniques, if available.
Authors are advised to consult "A fair press for animals" [New Scientist (1992) 1816: 18-30] before preparing their manuscript.
The Editors-in-Chief reserve the right to reject papers if there is doubt whether suitable procedures have been used.
III. Manuscript requirements
1. Form
(a) Manuscripts should be typewritten with one and a half or double spacing throughout and with margins at least 2.5 cm wide. If possible, A4 size (210 x 297 mm) paper should be used. Four copies of each manuscript should be submitted to facilitate reviewing by referees. It is only necessary to send photocopies of diagrams, or rough prints of halftones, with the third and fourth copies.
(b) Each manuscript must have a title page which includes only the title, the authors' names, the laboratory or origin, the name and address of the person to whom proofs should be mailed, including a Fax number and e-mail address where possible, and any necessary footnotes. Original manuscripts and diagrams are discarded 1 month after publication unless the Publisher is requested to return original material to the author. Corrections to the proof should be restricted to printer's errors. Substantial alterations may be charged to the author. Please note that authors are urged to check their proofs carefully before return, since late corrections to any articles cannot be guaranteed for inclusion in the printed journal.
(c) The title should be as short as is consistent with clarity. Papers should not be numbered in series, but sub-titles are accepted.
(d) A running title, not to exceed 56 letters and spaces, should be included on a separate sheet.
(e) Pages should be numbered in succession, the title page being page 1.
(f) Tables and figures should be on separate pages placed at the end of the manuscript. Their desired approximate locations should be indicated in the margin of the text.
(g) Footnotes to the text should be used sparingly; where they must be used their locations should be indicated by superscript numbers, and they should be typed with corresponding numbers on a separate sheet. In Tables, reference to footnotes should be made by the symbols *, , , ? , in that order.
(h) Greek characters should be clearly identified.
(i) Isotopic specifications should conform to the IUPAC system [Biochem. J. (1975) 145, 1-20].
(j) Drug names should be the official or approved names: trade names or common names may be given in brackets where the drug is rst mentioned. The manufacturer's name must be given. The doses of the drugs should be given as unit weight/unit body weight, e.g. mmol/kg or mg/kg. Concentrations should be given in terms of molarity, e.g. nM or M, or as unit weight/volume solution, stating whether the weight refers to the salt or the active component of the drug. The molecular weight, inclusive of water of crystallization, should be stated if doses are given as unit weight.
(k) The IUB Enzyme Commission (EC) number must be quoted with the full name of the enzyme when it is first mentioned in the text. Subsequently the accepted trivial name should be used, e.g. Full name: Acetyl-CoA: choline O-acetyl transferase (EC 2.3.1.6.) Trivial name: Choline acetyltransferase not choline acetylase. For this information the author should refer to Enzyme Nomenclature (1973), Elsevier, Amsterdam and the supplement in Biochim. Biophys. Acta (1976) 429, 1-45.
2. Style
(a) Manuscripts should be concisely written in English in a readily understandable style. Technical jargon, 'laboratory slang' or words not denied in dictionaries should not be used. Abbreviations should be avoided unless they conform to the instructions under sub-section 6. They must not be used as a short form for experimental procedures or for concepts.
(b) Redundant words, phrases, and sentences should not be used. For example, the captions of Tables and Figures, with or without paraphrasing, should not be repeated in the text. The Editors reserve the right to revise the wording of manuscripts accepted for publication in Neurochemistry International.
Authors should familiarize themselves with the format and style of recently published papers.
3. Organization
(a) Each paper must begin with a brief Abstract. It should not exceed 300 words. The first paragraph of the abstract should summarize the results obtained, the final paragraph should summarize the major conclusions in such a way that a reader not familiar with the techniques used can see any implications for his area of neuroscience. Abbreviations must not be used in the Abstract.
(b) The remaining text of all papers, however short, should be organized in the following four main sections:
(i) An introductory statement should first 'set the scene' for a non-specialist and then continue with the specific reasons for undertaking the investigation. Exhaustive reviews of the literature should be avoided and no attempt should be made to indicate the results obtained. The heading 'Introduction' should be omitted.
(ii) Experimental procedures. Procedures used should be given in sufficient detail to permit the repetition of the work by others. However, published procedures should only be briefly summarized and only described in detail if they have been substantially modified. Special chemicals, drugs, etc. with their sources of supply should be grouped under a separate subheading Materials.
(iii) Results. In this section findings should be described without discussion of their significance. Sub-sections should be used in order to clarify the expression of the results.
(iv) Discussion. In this section the authors' interpretations of their findings should be accompanied by an assessment of their significance in relation to previous work. Repetition of material given under 'Results' should be avoided. Sub-sections should be used wherever possible and sub-sections dealing with technical or highly specialized matter should be clearly separated from the rest of the text so that they can be printed in small type.
4. Presentation of data in tables or figures
(a) In general, tables and figures should be so constructed that they, together with their captions and legends, will be intelligible with minimal reference to the text.
(b) Each figure must be accompanied by a caption and explanatory legend typed on a separate sheet.
(c) Care should be taken to present data in a precise manner. For example, histograms should not be used when the data can equally well be given in a Table.
(d) Figures:
(i) Each figure must have its number, the authors' names and 'Neurochemistry International' written lightly on the reverse side.
(ii) Line drawings should be on white card or paper. Where possible, illustrations should be submitted in a form suitable for direct reproduction. Delay in publication is inevitable if figures require redrawing. Line drawings should normally be about twice the final size; in no case should the dimensions exceed 20 x 30 cm.
(iii) Symbols on graphs, etc. should be inserted by the author using the following standard characters:
?/P>
□ X +
5. References
(a) In the text, references should be quoted by giving author's name, followed by the year of publication in parentheses. For more than two authors, the name of the first author is given followed by the words 'et al.'.
(b) The reference list should be typed separately at the end of the manuscript in alphabetical order and arranged as follows: author's name and initials, year, title of the article, full journal title, volume, first and last page numbers.
For example:
Betz, H., Becker, C.-M., 1988. The mammalian glycine receptor: biology and structure of a neuronal chloride channel protein. Neurochemistry International 13, 137-146.
References to books should include the author's name and initials, year, title of book, volume, page numbers, publisher and place of publication. Where relevant, the title of a paper within a book, and the editor's names, should be given.
For example:
Baker, P. F., 1972. The sodium pump in animal tissues and its role in the control of cellular metabolism and function. In: Hopkin, L. E. (Ed.) Metabolic Pathways. Vol. 6, Academic Press, New York, pp. 243-268.
(c) Unpublished experiments may be mentioned only in the text; they must not be included in the list of References; initials as well as surnames must be given for authors whose unpublished experiments are quoted.
(d) A paper which has been accepted for publication but which has not appeared may be cited in the References with the abbreviated name of the Journal followed by the words 'In press'. The date of acceptance of each such paper should be indicated when the manuscript is submitted to Neurochemistry International.
(e) Personal communications may only be used when written authorization from the communicator is submitted with the original manuscript: they may only be mentioned in the text.
6. Abbreviations
(a) Symbols for physical units should be restricted to the Syst¨¨me Internationale (S.I.) Units. Examples of commonly used symbols can be found in Biochem J. (1975) 145, 1-20 and more detailed description, in Quantities, Units and Symbols (1971) The Royal Society, London.
(b) The excessive use of abbreviations in the text is strongly discouraged. In particular, awkward and unfamiliar abbreviations and those intended to express concepts or experimental techniques will not be permitted. In order to aid communication between scientists of different disciplines, authors should only use abbreviations sparingly and should always define the abbreviation when first used by placing it in parentheses after the full term, e.g. Acetylcholinesterase (AChE).
7. Chemical and biochemical nomenclature
As far as possible authors should follow the conventions used in The Biochemical Journal. See Biochem J. (1975) 145, 1-20.
8. Transfer of copyright
All authors must sign the Transfer of Copyright agreement before the article can be published. This transfer agreement enables Elsevier Ltd to protect the copyrighted material for the authors, but does not relinquish the author's proprietary rights. The copyright transfer covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations, and includes the right to adapt the article for use in conjunction with computer systems and programs, including reproduction or publication in machine-readable form and incorporation in retrieval systems. Authors are responsible for obtaining from the copyright holder permission to reproduce any figures for which copyright exists.
Editorial Board
Editors in Chief:
E. Sylvester Vizi, Institute of Experimental Medicine, Hungarian Academy of Sciences, H-1450 Budapest, P.O. Box 67, Hungary. Tel: +36 1 210 9421, Fax: +36 1 210 9424, Email: neurochem@koki.hu
Roger F. Butterworth, Neuroscience Research Unit, (Hôpital) Pavillon Saint-Luc-CHUM (Universit?de Montr¨¦al), 1058 St. Denis Street, Montr¨¦al, Qu¨¦bec, Canada H2X 3J4. Tel.: (+514) 281 2444 ext 5759, E-mail: butterwr@ERE.UMontreal.Ca Fax: (+514) 412 7314
Associate Editors:
Adrian Dunn, Louisiana State University Health Science Center, Shreveport, USA
Alan S. Hazell, Saint-Luc Hospital, Montreal, Canada
Josef Krieglstein, Institute of Pharmacology and Toxicology, Marburg, Germany
George Kunos, National Institute for Alcohol Abuse & Alcoholism, Bethesda, MD, USA
Max R¨¦casens, Universit?Montpellier II, Montpellier, France
Michael Robinson, Children's Hospital of Philadelphia/University of Pennsylvania, USA
Arne Schousboe, PharmaBiotec Research Center, Copenhagen, Denmark
Yukio Yoneda, Kanazawa University, Ishikawa, Japan
Editor Emeritus:
Neville N. Osborne, University of Oxford, Oxford, UK
Editorial Advisory Board:
T. Balla, National Institutes of Health, Bethesda, MD, USA
A.S. Basile, National Institutes of Health, Bethesda, MD, USA
S.C. Bondy, University of California, Irvine, CA, USA
G. Dienel, University Arkansas for Medical Sciences, Little Rock, AR, USA
P.R. Dodd, University of Queensland, St Lucia, Australia
K.G. Fuxe, Karolinska Institute, Stockholm, Sweden
G. Gibson, Burke Medical Research Institute, White Plains, NY, USA
D.D. Gilboe, University of Wisconsin Medical School, Madison, WI, USA
M. Göthert, Institute of Pharmacology and Toxicology, University of Bonn, Bonn, Germany
M. Hamon, INSERM U288, Paris, France
L.G. H¨¢rsing, EGIS Pharmaceuticals Ltd, Budapest, Hungary
P. Illes, University of Leipzig, Leipzig, Germany
F. Ito, Setsunan University, Osaka, Japan
M.P. Mattson, National Institute on Aging, Baltimore, MD, USA
M. Raiteri, Istituto di Farmacologia, Genoa, Italy
T.A. Reader, University of Montreal, Montreal, Canada
P.J. Richardson, University of Cambridge, Cambridge, UK
N. Saito, Kobe University, Kobe, Japan
L.S. Satin, Medical College of Virginia, Richmond, VA, USA
N. Sims, Flinders University, Adelaide, Australia
M. Smith, Case Western Reserve University, Cleveland, OH, USA
U. Sonnewald, N.T.N.U., Trondheim, Norway
H. Ueda, Nagasaki University School of Pharmacological Sciences, Nagasaki, Japan
M. Vignes, Universit?de Montpellier II, Montpellier, France
E. Weihe, University of Marburg, Marburg, Germany
R. Wenthold, National Institutes of Health, Bethesda, MD, USA
J.J. Woodward, Virginia Commonwealth University, Richmond, VA, USA
H. Zimmermann, Jw Goethe University Biozentrum, Frankfurt am Main, Germany
|
